Imlygic - direct healthcare professional communication (DHPC)

talimogene laherparepvec

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Imlygic (talimogene laherparepvec): Special considerations to minimize the potential occurrence of adverse events in HSV-1 seronegative patients receiving vials from affected lots: injections from ...

Dissemination date: 16/06/2022

Key facts

• Medicine name:
  Imlygic
• Active substance:
  talimogene laherparepvec
• Therapeutic area (MeSH):
  Melanoma
• Procedure number:
  EMEA/H/C/002771
• Regulatory outcome:
  Variation
• DHPC type:
  • Adverse event
  • Quality defect
• Human ATC codes:
  L01XX51
• Dissemination date:
  16/06/2022